Attovia Therapeutics, Inc. (ATTO)
13.83
-0.67
(-4.62%)
USD |
NASDAQ |
Oct 23, 16:00
13.83
0.00 (0.00%)
After-Hours: 20:00
Attovia Therapeutics Enterprise Value : 778.78M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 778.78M |
| October 22, 2026 | 809.36M |
| October 21, 2026 | 794.76M |
| October 20, 2026 | 788.36M |
| October 19, 2026 | 781.52M |
| October 16, 2026 | 774.21M |
| October 15, 2026 | 822.15M |
| October 14, 2026 | 830.36M |
| October 13, 2026 | 819.41M |
| October 12, 2026 | 813.47M |
| October 09, 2026 | 887.43M |
| October 08, 2026 | 891.99M |
| October 07, 2026 | 897.01M |
| October 06, 2026 | 946.32M |
| October 05, 2026 | 968.92M |
| October 02, 2026 | 931.25M |
| October 01, 2026 | 959.56M |
| September 30, 2026 | 929.88M |
| September 29, 2026 | 976.45M |
| September 28, 2026 | 953.17M |
| September 25, 2026 | 959.10M |
| September 24, 2026 | 976.90M |
| September 23, 2026 | 992.88M |
| September 22, 2026 | 1.098B |
| September 21, 2026 | 1.120B |
| Date | Value |
|---|---|
| September 18, 2026 | 1.158B |
| September 17, 2026 | 1.185B |
| September 16, 2026 | 1.163B |
| September 15, 2026 | 1.229B |
| September 14, 2026 | 1.267B |
| September 11, 2026 | 1.188B |
| September 10, 2026 | 1.176B |
| September 09, 2026 | 1.191B |
| September 08, 2026 | 1.228B |
| September 04, 2026 | 1.314B |
| September 03, 2026 | 1.252B |
| September 02, 2026 | 1.203B |
| September 01, 2026 | 1.162B |
| August 31, 2026 | 1.124B |
| August 28, 2026 | 1.092B |
| August 27, 2026 | 1.127B |
| August 26, 2026 | 1.040B |
| August 25, 2026 | 1.029B |
| August 24, 2026 | 1.089B |
| August 21, 2026 | 1.097B |
| August 20, 2026 | 1.070B |
| August 19, 2026 | 1.158B |
| August 18, 2026 | 1.208B |
| August 17, 2026 | 1.184B |
| August 14, 2026 | 1.054B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Alnylam Pharmaceuticals, Inc. | 29.64B |
| Agenus, Inc. | 534.42M |
| Amgen, Inc. | 280.78B |
| Anika Therapeutics, Inc. | 273.50M |
| BioCryst Pharmaceuticals, Inc. | 2.436B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -20.69M |
| Revenue (Quarterly) | 0.45M |
| Total Expenses (Quarterly) | 21.14M |
| EPS Diluted (Quarterly) | -0.4532 |
| Gross Profit Margin (Quarterly) | 45.33% |
| Profit Margin (Quarterly) | -4.60K% |
| Earnings Yield | -10.96% |
| Normalized Earnings Yield | -10.94 |